|
BIO INX, a leader in advanced bioinks for 3D bioprinting, and Carl Roth, a trusted name in research chemicals and laboratory supplies, announced their new distribution agreement. This collaboration marks Carl Roth’s first foray into the 3D bioprinting space, as the company continues its strategy of expanding into the rapidly growing 3D printing industry.
Through this partnership, Carl Roth will now offer BIO INX’s entire portfolio of bioinks, making these cutting-edge materials more accessible to researchers and scientists worldwide. This milestone enables Carl Roth to complement its existing 3D printing portfolio with innovative solutions tailored for tissue engineering, regenerative medicine, and other bioprinting applications.
“As a product manager for cell culture applications, I was concerned to establish a bioprinting portfolio at Carl Roth. During my academic work, I gained a clear understanding of the immense potential of bioprinting, as well as the challenges associated with it,” said Lia Heiser. ”So, in order to support research in this field, it was particularly important to me to offer high-quality and reliable bioinks - products I personally trust and stand behind."
BIO INX’s bioinks are designed to meet the diverse needs of the scientific community, with products optimized for various light-based and extrusion bioprinting technologies. While also focussing on clinical translation for example by including GMP-like inks in their portfolio. This collaboration with Carl Roth ensures researchers can benefit from efficient logistics and trusted support as they push the boundaries of scientific innovation.
"This partnership with Carl Roth is a great opportunity for BIO INX to streamline logistics and sales channels through one of the most well-known distributors of research chemicals and labware in the world," says Jasper Van Hoorick, CEO of BIO INX. "Every scientist is familiar with Carl Roth’s products, and their one-stop shop principle and this partnership brings our technology closer to clinical reality through more efficient logistics and trusted partnerships."
This collaboration reflects Carl Roth’s strategic expansion into 3D and bioprinting, showcasing the company’s commitment to staying at the forefront of technological innovation. By combining Carl Roth’s distribution network with BIO INX’s expertise in biomaterials, the partnership aims to accelerate advancements in bioprinting for both research and clinical applications.
BIO INX is a pioneering developer of materials for 3D bioprinting, committed to advancing the frontiers of healthcare through innovative solutions. As a spin-out from Ghent University and the Vrije Universiteit Brussel, BIO INX has established itself as a market leader in bioinks for high resolution bioprinting, focusing on materials for both extrusion- and light-based high-resolution printing technologies and offering a diverse portfolio of bioinks for various 3D bioprinting technologies.
|